<DOC>
	<DOCNO>NCT00468897</DOCNO>
	<brief_summary>The present pharmacokinetic study design compare bioavailability assess bioequivalence two Rosiglitazone XR formulation produce two different sites.Both formulation test fast healthy volunteer</brief_summary>
	<brief_title>A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR ( BRL-049653 ) 8mgs XR Manufactured At Two Different Sites .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Healthy male female age 1855 year . BMI 19 30 kg/m2 Exclusion criterion : Liver function test upper limit Excessive alcohol consumption history History Cigarette smoke Positive HIV , Hep B C test Positive pregnancy test History heparin sensitivity History glucose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Alzheimers Disease</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>